摘要
曲妥珠单抗是人表皮生长因子受体2(HER2)过表达乳腺癌患者的重要治疗手段之一。但即使是HER2高表达或是基因扩增的患者,曲妥珠单抗单药的有效率也仅为12%~34%,中位缓解期约9个月,许多患者在接受治疗的12个月内出现疾病进展。对曲妥珠单抗的耐药机制进行研究,有助于我们为曲妥珠单抗耐药的患者寻找新的治疗药物和方法。
Trastuzumab is one of the most important drugs for HER2 overexpressing breast cancer patients. However, even for these patients, the objective response rates to trastuzumab monotherapy are 12%-34%, and the median duration is about 9 months. Many patients progress within 12 months. Study of the mechanisms of resistance to trastuzumab will help us fi nd some new drugs and methods to overcome or delay the resistance.
出处
《中国癌症杂志》
CAS
CSCD
2008年第10期785-789,共5页
China Oncology
关键词
乳腺肿瘤
曲妥珠单抗
耐药
breast cancer
trastuzumab
drug resistance